Haploidentical hematopoietic stem cell transplantation in children with severe aplastic anemia
10.3969/j.issn.2095-4344.2014.23.027
- VernacularTitle:单倍体相合造血干细胞移植治疗儿童重型再生障碍性贫血
- Author:
Jingyuan LU
;
Quanyi LU
;
Jinzong LIN
;
Jiasheng HU
;
Xiuli HONG
;
Yamei CHEN
- Publication Type:Journal Article
- Keywords:
child;
anemia,aplastic;
hematopoietic stem celltransplantation;
immunosuppression;
placenta;
mesenchymal stem celltransplantation
- From:
Chinese Journal of Tissue Engineering Research
2014;(23):3768-3772
- CountryChina
- Language:Chinese
-
Abstract:
BACKGROUND:The main therapy of severe aplastic anemia in children is immunosuppressive therapy or stem celltransplantation, but the latter one is restricted due to few donor sources. Haploidentical hematopoietic stem celltransplantation is commonly used in leukemia, but it is stil rarely reported in the treatment of aplastic anemia. OBJECTIVE:To investigate the effect of haploidentical hematopoietic stem celltransplantation combined with placenta-derived mesenchymal stem celltransplantation for children with severe aplastic anemia. METHODS:A 7-year-old girl who had been confirmed as having severe aplastic anemia for 1.5 years received a cotransplantation of haploidentical hematopoietic stem cells combined with placenta-derived mesenchymal stem cells on July 9th , 2012. The donor was her mother. The preconditioning regimen consisted of fludarabine, cyclophosphamide, and anti-thymocyte globulin. RESULTS AND CONCLUSION:Time of neutrophil recovery (>0.5×10 9/L) was+9 days, and hematopoietic reconstruction was complete at+12 days. The short tandem repeat analysis showed 100%donor’s genotype at+100 days. Immunosuppressive drugs were stopped at+8 months, and no acute or chronic graft-versus-host disease occurred. With a fol ow-up of 18 months, she was in the disease-free survival period. Our findings suggest that the cotransplantation of al ogeneic haploidentical hematopoietic stem cells and placenta-derived mesenchymal stem cells is a new effective approach for children with severe aplastic anemia, which is worth exploring in the future.
